Evidence map›Paper›PMID 39010302›Full record

ArticleAlimentary pharmacology & therapeutics2024

Outcomes of patients with alcohol-associated hepatitis and acute kidney injury - Results from the HRS Harmony Consortium.

Ann T Ma, Andrew S Allegretti, Giuseppe Cullaro, Tianqui Ouyang, Sumeet K Asrani, Raymond T Chung, Eric M Przybyszewski, Robert M Wilechansky, Jevon E Robinson, Pratima Sharma and 12 more

Abstract readMulticenter Study
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Kidney safety net utilization after liver transplant for acute alcohol-associated hepatitis.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Ann T MaToronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0002-9059-111X
Andrew S AllegrettiDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Giuseppe CullaroDivision of Gastroenterology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.ORCID 0000-0002-2935-0245
Tianqui OuyangDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Sumeet K AsraniBaylor University Medical Center, Dallas, Texas, USA.ORCID 0000-0001-9174-5670
Raymond T ChungLiver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Eric M PrzybyszewskiLiver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Robert M WilechanskyLiver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jevon E RobinsonDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Pratima SharmaDepartment of Internal Medicine, University of Michigan Health, Ann Arbor, Michigan, USA.
Douglas A SimonettoDivision of Gastroenterology and Transplant Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Prasun JalalSection of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Eric S OrmanDivision of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Hani M WadeiDepartment of Transplantation, Mayo Clinic, Jacksonville, Florida, USA.
Shelsea A St HillienDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Danielle SalyDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Nneka N UfereLiver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-8255-9374
Leigh Anne DagefordeDepartment of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Kevin R RegnerDivision of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Justin M BelcherSection of Nephrology, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA.
Kavish R PatidarSection of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0003-3633-382X
from the HRS Harmony Consortium

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Y. Chen · 1986 to 2026
$30.7M
Personalizing Therapies for Acute Kidney Injury in CirrhosisK23DK128567 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Andrew S Allegretti · 2022 to 2026
$982k
Application of Novel Biomarkers of Renal Health in Cirrhosis Patients to Stratify Risk of Acute Kidney Injury Occurrence and ReversibilityK23DK131278 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Giuseppe Cullaro · 2022 to 2026
$812k
Development and Testing of an Integrated Care Coordination Intervention for Alcohol Use Disorder Recovery after Liver TransplantationK23AA031068 · NIAAA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Leigh Anne Dageforde · 2023 to 2026
$749k
American Association for the Study of Liver Diseases Clinical, Translational, and Outcomes Research AwardBristol-Myers SquibbGileadGlaxoSmithKlineMerckMGH Research Scholars ProgramNational Institutes of Healt K23AA031068National Institutes of Healt K23DK128567National Institutes of Healt K23DK131278National Institutes of Healt L30DK133959NCATS NIH HHS UL1 TR001863NIAAA NIH HHS K23 AA031068NIDDK NIH HHS K23 DK128567NIDDK NIH HHS K23 DK131278NIDDK NIH HHS L30 DK133959NIDDK NIH HHS P30 DK026743NIH HHS K23AA031068NIH HHS K23DK128567NIH HHS K23DK131278NIH HHS L30DK133959RocheUCSF Liver Center P30DK026743
6 · The paper itself

Abstract

BACKGROUND &

aimsThe development of acute kidney injury (AKI) in the setting of alcohol-associated hepatitis (AH) portends a poor prognosis. Whether the presence of AH itself drives worse outcomes in patients with cirrhosis and AKI is unknown.

methodsRetrospective cohort study of 11 hospital networks of consecutive adult patients admitted in 2019 with cirrhosis and AKI. AKI phenotypes, clinical course, and outcomes were compared between AH and non-AH groups.

resultsA total of 2062 patients were included, of which 303 (15%) had AH, as defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria. Patients with AH, compared to those without, were younger and had higher Model for End-stage Liver Disease-Sodium (MELD-Na) scores on admission. AKI phenotypes significantly differed between groups (p < 0.001) with acute tubular necrosis occurring more frequently in patients with AH. Patients with AH reached more severe peak AKI stage, required more renal replacement therapy, and had higher 90-day cumulative incidence of death (45% [95% CI: 39%-51%] vs. 38% [95% CI: 35%-40%], p = 0.026). Using no AH as reference, the unadjusted sHR for 90-day mortality was higher for AH (sHR: 1.24 [95% CI: 1.03-1.50], p = 0.024), but was not significant when adjusting for MELD-Na, age and sex. However, in patients with hepatorenal syndrome, AH was an independent predictor of 90-day mortality (sHR: 1.82 [95% CI: 1.16-2.86], p = 0.009).

conclusionsHospitalised patients with cirrhosis and AKI presenting with AH had higher 90-day mortality than those without AH, but this may have been driven by higher MELD-Na rather than AH itself. However, in patients with hepatorenal syndrome, AH was an independent predictor of mortality.

Indexed as

Acute Kidney InjuryHepatitis, AlcoholicAdultAgedFemaleHumansLiver CirrhosisMaleMiddle AgedPrognosisRenal Replacement TherapyRetrospective StudiesRisk FactorsSeverity of Illness IndexUnited States

Identifiers

PMID39010302
PMCPMC11349455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.